Y-Intercept (HK)’s Day One Biopharmaceuticals DAWN Stock Holding History

Y-Intercept (HK)’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-282,025	Closed	-$2.63M	–	1651
2025 Q4	$2.63M	Buy	+282,025	New	+$2.36M	0.06%	489
2025 Q3	–	Sell	-281,528	Closed	-$1.83M	–	1662
2025 Q2	$1.83M	Buy	+281,528	New	+$1.94M	0.04%	645
2024 Q3	–	Sell	-13,822	Closed	-$190K	–	1409
2024 Q2	$190K	Buy	+13,822	New	+$202K	0.01%	1185

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Y-Intercept (HK)'s DAWN Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 282,025 shares — an estimated $2.63M sold.

Y-Intercept (HK) first reported a position in DAWN in Q2 2024 and held it in 3 quarters. The position peaked at $2.63M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Y-Intercept (HK) reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 282,025 Day One Biopharmaceuticals shares in Q1 2026, an estimated $2.63M.
Y-Intercept (HK) first reported a position in Day One Biopharmaceuticals in Q2 2024 and held it in 3 quarters.
Y-Intercept (HK)'s Day One Biopharmaceuticals position peaked at $2.63M in Q4 2025.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.